{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=41", "query": { "condition": "LCC", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 1039, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T13:37:06.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00033462", "title": "Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Cholangiocellular Carcinoma", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Cholangiocarcinoma of the Gallbladder", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2002-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033462" }, { "nct_id": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Gastric Cancer", "Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "Advanced Solid Tumors", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreatic Cancer", "Melanoma" ], "interventions": [ { "name": "FATE-NK100", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-01-18", "completion_date": "2020-12-15", "has_results": false, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03319459" }, { "nct_id": "NCT04856046", "title": "Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Resectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2021-11-06", "completion_date": "2029-12-04", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04856046" }, { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT01556282", "title": "TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Cancer", "Portal Vein Thrombosis" ], "interventions": [ { "name": "TheraSphere", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2009-03", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-05-28", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01556282" }, { "nct_id": "NCT00513461", "title": "Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Liver Cancer", "Hepatitis C Infection" ], "interventions": [ { "name": "S-adenosyl-L-methionine disulfate p-toluene-sulfonate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "high performance liquid chromatography", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Chao Family Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2007-10", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2018-08-10", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 5, "location_summary": "Tucson, Arizona • Long Beach, California • Los Angeles, California + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513461" }, { "nct_id": "NCT02072356", "title": "Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer" ], "interventions": [ { "name": "yttrium Y 90 glass microspheres", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "TheraSphere", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "OTHER", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 290, "start_date": "2010-10-11", "completion_date": "2021-06-15", "has_results": false, "last_update_posted_date": "2022-09-30", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02072356" }, { "nct_id": "NCT00321594", "title": "Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer" ], "interventions": [ { "name": "belinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2006-05", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00321594" }, { "nct_id": "NCT04380545", "title": "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Fibrolamellar Carcinoma" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Recombinant Interferon Alpha 2b-like Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2021-01-13", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04380545" }, { "nct_id": "NCT00004108", "title": "DX-8951f in Treating Patients With Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "1999-09", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-10-28T13:37:06.275Z", "location_count": 4, "location_summary": "Denver, Colorado • New York, New York • Houston, Texas + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004108" } ] }